fluvastatin
Selected indexed studies
- Fluvastatin: A Choice for COVID-19-associated Mucormycosis Management. (Curr Med Chem, 2024) [PMID:37415368]
- Fluvastatin for lowering lipids. (Cochrane Database Syst Rev, 2018) [PMID:29508377]
- Fluvastatin. (Expert Opin Pharmacother, 2002) [PMID:12437496]
_Worker-drafted node — pending editorial review._
Connections
fluvastatin is a side effect of
Sources
- Fluvastatin: A Choice for COVID-19-associated Mucormycosis Management. (2024) pubmed
- Fluvastatin for lowering lipids. (2018) pubmed
- Fluvastatin. (2002) pubmed
- Clinical pharmacokinetics of fluvastatin. (2001) pubmed
- Fluvastatin treatment is not associated with an increased incidence of cancer. (2006) pubmed
- Enantiospecific Pharmacogenomics of Fluvastatin. (2019) pubmed
- Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. (1996) pubmed
- Fluvastatin: a review of its use in lipid disorders. (1999) pubmed
- Fluvastatin: clinical and safety profile. (2004) pubmed
- Fluvastatin in combination with other lipid-lowering agents. (1996) pubmed